Preservation of fertility in female patients with hematologic diseases

IF 6.9 2区医学 Q1 HEMATOLOGY

Blood Reviews Pub Date : 2023-11-01 DOI:10.1016/j.blre.2023.101115

Marika Bini Antunes , Sara Pinto Cardeal , Manuel Magalhães , Emídio Vale-Fernandes , Márcia Barreiro , Rosália Sá , Mário Sousa

{"title":"Preservation of fertility in female patients with hematologic diseases","authors":"Marika Bini Antunes , Sara Pinto Cardeal , Manuel Magalhães , Emídio Vale-Fernandes , Márcia Barreiro , Rosália Sá , Mário Sousa","doi":"10.1016/j.blre.2023.101115","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Recent developments of assisted reproduction techniques<span> turned possible to avoid the infertility consequences of oncologic treatments, but </span></span>fertility preservation<span> (FP) has been somewhat neglected in women with hematologic diseases undergoing gonadotoxic treatments. For these specific cases, the current options for FP include the </span></span>cryopreservation<span> of embryos, mature oocytes and ovarian tissue, and oocyte in-vitro maturation. We intend to make patients and clinicians aware of this important and relevant issue, and provide hematologists, assisted reproduction physicians and patients, with updated tools to guide decisions for FP. The physicians of the units responsible for female FP should always be available to decide on the best-individualized FP option in strict collaboration with hematologists. With a wide range of options for FP tailored to each case, a greater level of training and information is needed among clinicians, so that patients proposed to gonadotoxic treatments can be previously advised for FP techniques in hematological conditions.</span></p></div><div><h3>Abbreviated abstract</h3><p>Recent developments of assisted reproduction techniques turned possible to preserve the fertility of women with hematologic diseases undergoing gonadotoxic treatments.</p><p>Current options for fertility preservation in women with hematologic diseases are presented.</p><p>It is imperative to offer fertility preservation to all women before starting any gonadotoxic treatment and in some cases after treatment.</p><p>Fertility preservation methods enable to later achieve the desired pregnancy</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000760","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Recent developments of assisted reproduction techniques turned possible to avoid the infertility consequences of oncologic treatments, but fertility preservation (FP) has been somewhat neglected in women with hematologic diseases undergoing gonadotoxic treatments. For these specific cases, the current options for FP include the cryopreservation of embryos, mature oocytes and ovarian tissue, and oocyte in-vitro maturation. We intend to make patients and clinicians aware of this important and relevant issue, and provide hematologists, assisted reproduction physicians and patients, with updated tools to guide decisions for FP. The physicians of the units responsible for female FP should always be available to decide on the best-individualized FP option in strict collaboration with hematologists. With a wide range of options for FP tailored to each case, a greater level of training and information is needed among clinicians, so that patients proposed to gonadotoxic treatments can be previously advised for FP techniques in hematological conditions.

Abbreviated abstract

Recent developments of assisted reproduction techniques turned possible to preserve the fertility of women with hematologic diseases undergoing gonadotoxic treatments.

Current options for fertility preservation in women with hematologic diseases are presented.

It is imperative to offer fertility preservation to all women before starting any gonadotoxic treatment and in some cases after treatment.

Fertility preservation methods enable to later achieve the desired pregnancy

Abstract Image

查看原文本刊更多论文

女性血液病患者生育能力的保存

辅助生殖技术的最新发展使避免肿瘤治疗导致的不孕不育成为可能，但在接受性腺毒素治疗的血液病妇女中，生育能力保存(FP)在某种程度上被忽视了。对于这些特殊病例，目前的计划生育选择包括胚胎、成熟卵母细胞和卵巢组织的冷冻保存，以及卵母细胞体外成熟。我们打算让患者和临床医生意识到这一重要而相关的问题，并为血液学家、辅助生殖医生和患者提供最新的工具来指导计划生育的决策。负责女性计划生育的单位的医生应始终与血液学家严格合作，决定最佳的个性化计划生育方案。由于针对每个病例有广泛的计划生育选择，临床医生需要更高水平的培训和信息，以便建议接受促性腺毒素治疗的患者可以事先建议在血液学条件下使用计划生育技术。最近的辅助生殖技术的发展使那些接受促性腺毒素治疗的血液病妇女保持生育能力成为可能。目前的选择生育保存妇女与血液病提出。在开始任何促性腺毒素治疗之前和在某些情况下治疗后，必须向所有妇女提供生育能力保护。保留生育能力的方法可以在以后实现期望的怀孕

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Reviews 医学-血液学

CiteScore

13.80

自引率

1.40%

发文量

期刊介绍： Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.